Research programme: cancer therapeutics - Paradigm PharmaceuticalsAlternative Names: Caspase stimulants research programme - Paradigm Pharmaceuticals; LFM A12; LFM A13
Latest Information Update: 06 Sep 2010
At a glance
- Originator Paradigm Pharmaceuticals
- Class Isoxazoles; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Caspase stimulants; Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Dec 1999 Preclinical trials in Cancer in USA (unspecified route)